Healthcare >> Analyst Interviews >> September 30, 2020
Midcap and Small-Cap Biopharma Opportunities a Better Way to Go in 2021
Hartaj Singh is Managing Director and Senior Analyst, Biotechnology at Oppenheimer & Co. Inc. Earlier, Mr. Singh was Managing Director and Senior Biotechnology Analyst at BTIG Securities. He began his sellside career at Lehman Brothers and subsequently moved to the buy side covering biotechnology at Visium Asset Management and Tecumseh Partners. He began his career as a clinical trial project manager for ClinTrials Research and also worked as a strategic analysis manager for Johnson & Johnson, both of which give him experience in clinical trial design. Mr. Singh has a B.A. in biology from Case Western Reserve University and also did graduate work in computational neurobiology. He received an MBA from Duke University’s Fuqua School of Business. Profile
Word count: 4,882
TWST: What's your coverage at Oppenheimer & Co.?
Mr. Singh: My team and I cover essentially everything from very large companies, like